肝细胞癌患者的个体化管理:多参数治疗层级概念
本文评述肝细胞癌治疗分配从基于分期转向个体化方法,提出多参数治疗层级概念,按生存获益排序治疗选项,并引入反向治疗层级概念,按转化或辅助能力排序。
要点
- 肝细胞癌手术与系统治疗进展增加了管理复杂性,需动态调适分期算法。
- 真实世界管理依赖非分期因素,如衰弱、合并症负担、肿瘤位置、肝功能参数等。
- 提出多参数治疗层级按生存获益排序,反向层级按转化或辅助能力排序。
核心结论
- 提出基于证据的肝细胞癌治疗框架,采用多参数治疗层级概念,按生存获益从手术到系统治疗排序,并引入反向治疗层级按转化或辅助能力从系统治疗到手术排序。
研究设计与样本
- 本文为政策综述,批判性评估治疗分配从基于治疗前分期特征转向更个体化治疗方法,其中专家肿瘤委员会发挥核心作用。
主要发现
- 真实世界肝细胞癌管理日益依赖独立于肿瘤学分期的因素,包括患者衰弱、合并症负担、关键肿瘤位置、多个肝功能参数、影响治疗实施的具体技术禁忌证和资源可用性。
关键数值与推荐
- 多参数治疗层级中,不同治疗选项按生存获益排序,即从手术到系统治疗。
- 反向治疗层级中,治疗按转化能力或辅助能力排序,即从系统治疗到手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).
引用
- Vitale A, Cabibbo G, Iavarone M, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023. PMID: 37414020. doi:10.1016/S1470-2045(23)00186-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。